Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results Aug 9, 2024 04:20PM
Edesa Biotech (EDSA): BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS Jun 24, 2024 08:21AM
BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS Jun 24, 2024 08:20AM
Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results May 10, 2024 04:15PM
Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference Apr 11, 2024 09:00AM
View Older Stories

Apr 2, 2024 09:00AM Edesa Biotech to Participate in Upcoming Investor Conferences
Mar 21, 2024 04:30PM Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference
Mar 7, 2024 08:45AM Edesa Biotech to Participate in Barclays Global Healthcare Conference
Mar 4, 2024 04:30PM Edesa Biotech to Participate in Upcoming Dermatology Meetings
Feb 9, 2024 04:15PM Edesa Biotech Reports Fiscal 1st Quarter 2024 Results
Jan 4, 2024 04:15PM Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week
Dec 15, 2023 04:10PM Edesa Biotech Reports Fiscal Year 2023 Results
Nov 20, 2023 04:08PM Edesa Biotech (EDSA) Reports Final Phase 2b Results for Dermatitis Study
Nov 20, 2023 04:05PM Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study
Oct 26, 2023 04:05PM Edesa Biotech to Present at Dermatology Drug Development Summit
Oct 25, 2023 09:12AM Edesa Biotech (EDSA) Announces Approval of Updated Phase 3 Trial Design for ARDS Drug
Oct 25, 2023 09:10AM Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech’s ARDS Drug
Oct 12, 2023 12:17PM Edesa Biotech (EDSA) Secures $10M Credit Facility with Founder Par Nijhawan
Oct 12, 2023 12:15PM Edesa Biotech Secures $10 Million Credit Facility with Company Founder
Oct 12, 2023 12:12PM Edesa Biotech (EDSA) to Receive Up To C$23 Million in Funding from Federal Government
Oct 12, 2023 12:10PM Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government
Oct 10, 2023 09:03AM Edesa Biotech (EDSA) Announces 1:7 Reverse Share Split
Oct 10, 2023 09:00AM Edesa Biotech Announces One-for-Seven Reverse Share Split
Sep 28, 2023 08:15AM Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate
Aug 9, 2023 04:15PM Edesa Biotech Reports Fiscal Third Quarter 2023 Results
Jul 26, 2023 09:00AM Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference
Jun 28, 2023 07:56AM Edesa Biotech's (EDSA) ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens
Jun 28, 2023 07:55AM Edesa Biotech's ARDS Drug Inhibits Inflammation from Influenza and Other Pathogens
Jun 27, 2023 08:17AM Edesa Biotech (EDSA) Appoints Stephen Lemieux as CFO
Jun 27, 2023 08:15AM Edesa Biotech Appoints Biotech Deal Veteran to CFO Role
May 11, 2023 04:30PM Edesa Biotech Reports Fiscal 2nd Quarter 2023 Results
Apr 20, 2023 08:30AM Edesa Biotech to Participate in Swiss Biotech Day
Apr 4, 2023 08:45AM The WHO and USAN Adopt Generic Name for Edesa's ARDS Drug Candidate
Mar 23, 2023 04:30PM Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Disease Conference
Mar 16, 2023 04:10PM Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting
Mar 15, 2023 08:13AM Edesa Biotech (EDSA) and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study
Mar 15, 2023 08:10AM Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study
Feb 10, 2023 09:00AM Edesa Biotech Reports Fiscal 1st Quarter 2023 Results
Feb 1, 2023 08:17AM Edesa Biotech (EDSA) Receives Regulatory Approval for Phase 2 Vitiligo Study
Feb 1, 2023 08:15AM Edesa Biotech Receives Regulatory Approval for Phase 2 Vitiligo Study
Jan 17, 2023 08:33AM Edesa Biotech (EDSA) Reports Prelim Topline Phase 2b Results for EB01
Jan 17, 2023 08:30AM Edesa Biotech Reports Topline Phase 2b Results for Dermatology Drug
Dec 20, 2022 08:32AM Edesa Biotech (EDSA) Granted FDA Fast Track Designation to its ARDS Drug Candidate
Dec 20, 2022 08:30AM FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate
Dec 16, 2022 09:00AM Edesa Biotech Reports Fiscal Year 2022 Results
Dec 2, 2022 08:00AM Edesa Biotech to Participate in the 2022 Cantor Fitzgerald Dermatology Conference
Nov 3, 2022 09:00AM Edesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-Market
Sep 30, 2022 08:03AM Edesa Biotech (EDSA) Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study
Sep 30, 2022 08:00AM Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study
Sep 8, 2022 04:30PM Edesa Biotech to Present at Upcoming H.C. Wainwright Investor Conference
Sep 7, 2022 08:00AM Edesa Biotech Reports Phase 2b Study Reaches Full Enrollment
Aug 12, 2022 04:30PM Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results
Aug 3, 2022 08:15AM Edesa Biotech to Participate at the Upcoming BTIG Biotech Conference
Jul 11, 2022 08:30AM Edesa Biotech to Present at ARDS Drug Development Summit
May 24, 2022 07:57AM Edesa Biotech (EDSA) Adds Mechanically Ventilated Patients to Phase 3 ARDS Study
View Older Stories